IL17A and psoriasis: Secukinumab (SEC) and ixekizumab (IXE) are monoclonal antibodies targeting IL-17A, and brodalumab (BRO) is a fully human monoclonal antibody targeting the IL-17 receptor A. All of them have demonstrated high efficacy for psoriasis in clinical settings [7].